Drug Approval | January 17, 2025
FDA issues five observations to Jubilant Pharmova’s Salisbury facility in USA
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Morepen Laboratories approves hiving off of medical devices business
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure
Biocon Biologics remains committed to global standards of quality and compliance
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Subscribe To Our Newsletter & Stay Updated
